



2022 Statistical Report

Lehigh Valley Topper Cancer Institute Mission

We ease our community's cancer burden by preventing cancer, finding cancer early, providing comprehensive diagnostic, consultative, treatment, support and survivorship services, and by educating health care professionals and residents of the communities we serve about advances in cancer care.



WELCOME TO LEHIGH VALLEY TOPPER CANCER INSTITUTE'S 2022 ANNUAL REPORT, which features our statistical data (CY 2021) and insight into the programs, services and innovations in cancer care. Our cancer program continues to navigate the changes and impact brought about by the COVID-19 pandemic while remaining true to our mission of providing outstanding, safe, timely and quality care to our patients and community.


Lehigh Valley Topper Cancer Institute, part of Lehigh Valley Health Network, offers diverse and many innovative and leading-edge services. They include prevention, detection, diagnosis, genetics, patient navigation, nutrition, social and psychological support, rehabilitation, clinical trials, multidisciplinary and coordinated care, surgery, radiation therapy, chemotherapy, immunotherapy, hemophilia care, survivorship, palliative care and hospice support.

Cancer Data Management

The cancer data management department of Lehigh Valley Topper Cancer Institute captures a complete summary of the demographics, history, diagnosis, treatment and health status for every cancer patient who presents in our facilities. The data is extracted and stored in a secured cancer registry database, a software information system designed for the collection, management and analysis of data on cancer patients – including survivors and those diagnosed with benign brain tumors. Also, the cancer registry is maintained with timely and accurate data to capture cancer incidence, evaluate treatment efficacy and determine survivorship.

In turn, this information is utilized by medical clinicians, as well as by local, state and national agencies, including the Pennsylvania Cancer Registry, Department of Health and the Commission on Cancer's Rapid Reporting System. Cancer registry data provides important information to health care clinicians, researchers and public health officials to enhance monitoring, advance cancer treatments and research and improve cancer screening and prevention programs.

LEHIGH VALLEY HEALTH NETWORK – 2021 ENCOUNTERS



LVH–Cedar Crest, LVH–Muhlenberg, LVH–Hecktown Oaks, LVHN–Coordinated Health, LVH–Hazleton, LVH–Pocono, LVH–Schuylkill, LVHN–Steamtown

Cancer Staging and Incidence Terminology

Cancer diagnosis, staging, incidence and treatment have a language of their own. Here are some commonly used terms and resources for more information:

AMERICAN JOINT COMMITTEE ON CANCER (AJCC) STAGING

A classification system used for describing the extent of disease progression based on the evaluation of the tumor size/invasion, nodal status and metastasis at the time of diagnosis. AJCC staging is important in determining treatment plans.

ANALYTIC CANCER CASE

Cases for which the facility provided the initial diagnosis of cancer and/or for which the facility contributed to all or part of the first course of treatment.

NATIONAL CANCER DATABASE (NCDB)

The NCDB, a joint project of the American Cancer Society and the Commission on Cancer (CoC), collects information on cancer cases diagnosed and/or treated at hospitals throughout the country. This patient-anonymous information is used to present scientifically reviewed descriptions of patient diagnosis, treatment and outcome. The most recent data from NCDB for comparison is on cases newly diagnosed in 2020.

RAPID CANCER REPORTING SYSTEM (RCRS)


The CoC's National Cancer Database has implemented a change to its technology infrastructure, with the transition to a new data platform system referred to as the RCRS, formerly known as RQRS.

RCRS, launched on Sept. 28, 2020, is a web-based data collection and reporting system that analyzes information gathered through the American College of Surgeons' Quality Data Platform vendor, IQVIA. RCRS now serves as the new single-source of data submission for all CoC-accredited hospital registries resulting from the combining of the prior two systems, RQRS and NCDB. Cases submitted to RCRS will include all disease sites from 2007 and going forward.

Lehigh Valley Topper Cancer Institute actively participates in the RCRS data collection and reporting program. As a nationwide oncology case repository for real-time and historical data, RCRS enables assessment of hospital-level adherence to quality of cancer care measures for all CoC-accredited programs. Resulting case analysis contributes to a body of evidence-based cancer care knowledge. Based on the evidence, RCRS alerts participants each month to "anticipated care" for their cancer patients. The value in these alerts is to avoid having patients miss out on adjuvant care or therapy that they could receive in addition to their main treatment plan.



TOP FIVE CANCER PRIMARIES, LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVH-COORDINATED HEALTH (FIVE-YEAR COMPARISON)

SITE DESCRIPTION	2017	2018	2019	2020	2021
BREAST	504	559	568	578	684
PROSTATE GLAND	290	377	410	432	526
BRONCHUS AND LUNG	446	471	479	428	462
COLON/RECTAL	267	281	266	259	286
BLOOD AND BONE MARROW	226	232	206	181	218
TOTAL	1,733	1,920	1,929	1,878	2,176




*LVH-Cedar Crest, LVH-Muhlenberg, LVH-Hecktown Oaks, LVH-Coordinated Health

Total Annual Analytic Cases




Top Five Most Prevalent Sites of Cancer Treated at Lehigh Valley Health Network Regional Centers


LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH




LVH-HAZLETON



LVH-SCHUYLKILL




LVH-POCONO



Data source: Lehigh Valley Topper Cancer Institute tumor registry


Case Classification Based on Patient Migration Patterns

ANALYTIC CASES, LVH-CEDAR CREST, LVH-MUHLENBERG AND LVHN-COORDINATED HEALTH, 2021



- Diagnosed here and treated here
- Diagnosed elsewhere and treated here
- Diagnosed here and treated elsewhere

Non-Analytic Class of Case Volumes by LVHN Facility, 2021



Non-analytic cases represent any of the following scenarios: patients who present at LVH after initial diagnosis and/or treatment elsewhere, and patient is referred for consultation, recurrence of cancer, or disease progression; pathology specimen only; diagnosed and received all first course of treatment in a staff physician's office; or initially diagnosed at autopsy or death certificate.

Analytic Case Incidence by County of Residence, Five-Year Comparison

Lehigh Valley Topper Cancer Institute (LVH-Cedar Crest, LVH-Muhlenberg, LVH-Hecktown Oaks and LVHN-Coordinated Health) provides cancer care for patients in our community and serves as a tertiary referral center. In 2021, we provided diagnostic care, second-opinion recommendations and treatment to more than **4,200** patients from **25** Pennsylvania counties. In addition, **79** patients came to our cancer program from communities across the United States.

COUNTY OF RESIDENCE	2017	2018	2019	2020	2021
ADAMS	0	0	1	0	0
BEDFORD	0	0	0	1	0
BERKS	226	277	278	270	289
BRADFORD	0	3	0	0	0
BUCKS	45	55	50	44	54
BUTLER	0	0	1	0	0
CAMBRIA	1	0	1	0	0
CARBON	227	186	198	151	191
CENTRE	1	0	0	0	1
CHESTER	4	8	7	5	6
CLINTON	0	1	0	0	0
COLUMBIA	0	4	6	4	4
CUMBERLAND	1	1	1	1	2
DAUPHIN	1	1	0	1	1
DELAWARE	2	0	1	2	0
GREENE	0	1	0	0	0
INDIANA	0	0	1	0	0
JEFFERSON	0	2	0	0	0
LACKAWANNA	28	41	42	31	32
LANCASTER	3	0	1	0	0
LEBANON	1	0	1	1	3
LEHIGH	1,566	1,470	1,453	1,479	1,700
LUZERNE	133	153	170	177	211
LYCOMING	2	3	0	0	0
MERCER	0	0	0	0	1
MONROE	154	151	155	144	179
MONTGOMERY	83	71	72	57	78
NORTHAMPTON	764	920	949	992	1,113
NORTHUMBERLAND	1	2	1	1	2
PERRY	0	0	1	0	0
PHILADELPHIA	3	1	1	1	1
PIKE	15	24	19	11	22
POTTER	0	1	0	0	1
SCHUYLKILL	204	228	269	222	249
SNYDER	0	0	0	1	0
SOMERSET	1	0	0	0	0
SULLIVAN	0	0	0	2	0
SUSQUEHANNA	2	5	2	2	3
UNION	0	0	1	0	0
TIOGA	1	2	0	0	0
VENANGO	0	1	0	0	0
WARREN	0	0	0	0	1
WAYNE	10	13	11	7	8
WYOMING	5	3	3	3	5
YORK	0	1	0	0	0
OUT OF STATE	73	57	42	70	79
TOTAL	3,557	3,686	3,738	3,680	4,236

Analytic Cases by Primary Body Site, 2021

LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

PRIMARY SITE	TOTAL
HEAD AND NECK	117
DIGESTIVE ORGANS	627
ESOPHAGUS	51
STOMACH	41
SMALL INTESTINE	28
COLON	213
RECTOSIGMOID JUNCTION	13
RECTUM	60
ANUS AND ANAL CANAL	9
LIVER AND BILE DUCTS	64
GALLBLADDER	9
OTHER BILIARY TRACT	12
PANCREAS	126
OTHER DIGESTIVE ORGANS	1
THORAX	475
BRONCHUS AND LUNG	462
THYMUS	6
HEART MEDIASTINUM PLEURA	7
MUSCULOSKELETAL/SOFT TISSUE SITES	39
BLOOD AND BONE MARROW	218

PRIMARY SITE	TOTAL
SKIN	162
BREAST	684
FEMALE GENITAL ORGANS	309
VULVA	22
VAGINA	6
CERVIX UTERI	18
CORPUS UTERI	202
UTERUS NOS	5
OVARY	53
OTHER FEMALE GENITAL ORGANS	3
MALE GENITAL ORGANS	547
PENIS	4
PROSTATE GLAND	526
TESTIS	16
OTHER AND UNSPECIFIED MALE GENITAL ORGANS	1
URINARY TRACT ORGANS	357
KIDNEY	141
KIDNEY, RENAL PELVIS	13
URETER	10
URINARY BLADDER	190
OTHER AND UNSPECIFIED URINARY ORGANS	3

PRIMARY SITE	TOTAL
CENTRAL NERVOUS SYSTEM	291
MENINGES	183
BRAIN	78
OTHER NERVOUS SYSTEM	30
ENDOCRINE GLANDS	203
THYROID GLAND	157
ADRENAL GLAND	5
OTHER ENDOCRINE GLANDS	41
OTHER	14
PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM	1
RETROPERITONEUM AND PERITONEUM	12
OTHER ILL-DEFINED SITES	1
LYMPH NODES	127
UNKNOWN PRIMARY	66
TOTAL ANALYTIC CASES	4,236

LVH-HAZLETON

PRIMARY SITE	TOTAL
HEAD AND NECK	14
DIGESTIVE ORGANS	63
BRONCHUS AND LUNG	55
MUSCULOSKELETAL/SOFT TISSUE SITES	2
BLOOD AND BONE MARROW	26
SKIN	4
BREAST	59
FEMALE GENITAL ORGANS	21
MALE GENITAL ORGANS	38
URINARY TRACT ORGANS	29
CENTRAL NERVOUS SYSTEM	22
ENDOCRINE GLANDS	13
RETROPERITONEUM AND PERITONEUM	1
LYMPH NODES	11
UNKNOWN PRIMARY	7
TOTAL ANALYTIC CASES	365

LVH-SCHUYLKILL

PRIMARY SITE	TOTAL
HEAD AND NECK	21
DIGESTIVE ORGANS	50
BRONCHUS AND LUNG/THORAX	57
MUSCULOSKELETAL/SOFT TISSUE SITES	2
BLOOD AND BONE MARROW	17
SKIN	2
BREAST	43
FEMALE GENITAL ORGANS	29
PROSTATE GLAND	7
URINARY TRACT ORGANS	20
CENTRAL NERVOUS SYSTEM	14
ENDOCRINE GLANDS	12
RETROPERITONEUM AND PERITONEUM	1
LYMPH NODES	12
UNKNOWN PRIMARY	10
TOTAL ANALYTIC CASES	297

#1 Breast Cancer, 2021

INCIDENCE OF BREAST CANCER BY AGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-103	TOTAL
(N)	1	18	84	162	183	166	60	10	684

BREAST CANCER TREATMENT BY AJCC STAGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

TREATMENT	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	LVHN TOTAL*	LVHN %
SURGERY + RADIATION + HORMONE THERAPY	34	134	7	0	0	8	183	28.8%
SURGERY ALONE	28	66	6	1	0	12	113	17.8%
SURGERY + HORMONE THERAPY	7	61	3	0	0	10	81	12.8%
SURGERY + RADIATION THERAPY	30	35	2	1	0	6	74	11.7%
SURGERY + CHEMOTHERAPY	1	16	10	2	0	1	30	4.7%
SURGERY + CHEMOTHERAPY + RADIATION + HORMONE THERAPY	0	12	5	4	0	1	22	3.5%
SURGERY + CHEMOTHERAPY + IMMUNOTHERAPY	0	12	1	1	0	0	14	2.2%
SURGERY + CHEMOTHERAPY + RADIATION + HORMONE + IMMUNOTHERAPY	0	12	0	0	0	0	12	1.9%
CHEMOTHERAPY + HORMONE THERAPY	0	0	0	0	12	0	12	1.9%
SURGERY + CHEMOTHERAPY + HORMONE THERAPY	0	5	0	3	2	2	12	1.9%
CHEMOTHERAPY + IMMUNOTHERAPY	0	0	4	3	3	0	10	1.6%
HORMONE ALONE	0	6	2	0	2	0	10	1.6%
SURGERY + CHEMOTHERAPY + RADIATION THERAPY	0	6	1	1	0	0	8	1.3%
SURGERY + CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	2	4	0	0	0	6	0.9%
SURGERY + CHEMOTHERAPY + HORMONE + IMMUNOTHERAPY	0	4	1	0	0	0	5	0.8%
CHEMOTHERAPY ALONE	0	1	0	2	1	0	4	0.6%
SURGERY + HORMONE + IMMUNOTHERAPY	0	0	1	0	0	0	1	0.2%
CHEMOTHERAPY + HORMONE + IMMUNOTHERAPY	0	0	0	0	1	0	1	0.2%
CHEMOTHERAPY + RADIATION + HORMONE + IMMUNOTHERAPY	0	0	0	0	1	0	1	0.2%
CHEMOTHERAPY + RADIATION + HORMONE THERAPY	0	0	0	0	1	0	1	0.2%
HORMONE + IMMUNOTHERAPY	0	0	0	0	1	0	1	0.2%
IMMUNOTHERAPY ALONE	0	0	0	0	1	0	1	0.2%
RADIATION ALONE	1	0	0	0	0	0	1	0.2%
NO FIRST-COURSE TREATMENT	5	9	0	2	10	6	32	5.0%
TOTAL	106	381	47	20	35	46	635	100%

*44 cases excluded because of stage classification performed after initial multimodality therapy

*Five cases excluded because of histologies not having a staging classification (e.g., phyllodes tumor and lobular carcinoma in situ, or LCIS)

#2 Prostate Cancer, 2021

INCIDENCE OF PROSTATE CANCER BY AGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-100	TOTAL
(N)	0	0	5	69	223	183	43	3	526

PROSTATE CANCER TREATMENT BY AJCC STAGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

TREATMENT	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	LVHN TOTAL	LVHN %
RADIATION + HORMONE THERAPY	0	50	31	26	22	129	24.5%
SURGERY ALONE	19	66	30	5	6	126	24.0%
RADIATION ALONE	3	40	2	0	8	53	10.1%
HORMONE ALONE	0	3	5	28	3	39	7.4%
SURGERY + HORMONE THERAPY	0	6	10	5	1	22	4.2%
SURGERY + RADIATION + HORMONE THERAPY	0	0	6	7	1	14	2.7%
SURGERY + RADIATION THERAPY	0	2	1	0	0	3	0.6%
CHEMOTHERAPY ALONE	0	0	1	0	0	1	0.2%
CHEMOTHERAPY + HORMONE THERAPY	0	0	0	1	0	1	0.2%
CHEMOTHERAPY + RADIATION + HORMONE THERAPY	0	0	0	1	0	1	0.2%
NO FIRST-COURSE TREATMENT	68	35	2	0	32	137	26.0%
TOTAL	90	202	88	73	73	526	100%

#3 Lung Cancer, 2021

INCIDENCE OF LUNG CANCER BY AGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-100	TOTAL
(N)	0	1	10	45	151	167	78	10	462

LUNG CANCER TREATMENT BY AJCC STAGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

TREATMENT	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	STAGE NA	LVHN TOTAL	LVHN %
RADIATION ALONE	0	87	9	1	24	0	1	122	26.4%
SURGERY ALONE	3	59	4	0	0	0	0	66	14.3%
CHEMOTHERAPY + RADIATION THERAPY	0	4	4	26	18	2	0	54	11.7%
CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	0	0	13	27	1	0	41	8.9%
CHEMOTHERAPY + IMMUNOTHERAPY	0	1	0	1	25	0	0	27	5.8%
CHEMOTHERAPY ALONE	0	0	1	1	16	0	0	18	3.9%
SURGERY + CHEMOTHERAPY	1	1	10	3	1	0	0	16	3.5%
IMMUNOTHERAPY ALONE	0	1	0	2	6	1	0	10	2.2%
RADIATION + IMMUNOTHERAPY	0	0	0	2	4	0	0	6	1.3%
SURGERY + CHEMOTHERAPY + RADIATION THERAPY	0	0	0	3	1	0	0	4	0.9%
SURGERY + RADIATION THERAPY	0	1	1	0	0	0	0	2	0.4%
SURGERY + CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	0	0	2	0	0	0	2	0.4%
SURGERY + CHEMOTHERAPY + IMMUNOTHERAPY	0	0	0	1	1	0	0	2	0.4%
NO FIRST-COURSE TREATMENT	0	15	2	16	58	1	0	92	19.9%
TOTAL	4	169	31	71	181	5	1	462	100%

#4 Colon Cancer, 2021

INCIDENCE OF COLON CANCER BY AGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

AGE AT DIAGNOSIS	0-19	20-29	30-39	40-49	50-59	60-69	70-79	80-89	90-100	TOTAL
(N)	3	2	3	15	39	52	55	37	7	213

COLON CANCER TREATMENT BY AJCC STAGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

TREATMENT	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	LVHN TOTAL*	LVHN %
SURGERY ALONE	6	33	33	16	7	12	107	51.2%
SURGERY + CHEMOTHERAPY	0	0	11	27	9	1	48	23.0%
CHEMOTHERAPY + IMMUNOTHERAPY	0	0	0	0	8	0	8	3.8%
SURGERY + CHEMOTHERAPY + IMMUNOTHERAPY	0	0	0	1	6	0	7	3.3%
CHEMOTHERAPY ALONE	0	0	0	0	7	0	7	3.3%
IMMUNOTHERAPY ALONE	0	0	0	0	1	2	3	1.4%
SURGERY + IMMUNOTHERAPY	0	0	0	0	2	0	2	1.0%
SURGERY + CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	0	0	0	1	0	1	0.5%
NO FIRST-COURSE TREATMENT	1	0	0	2	17	6	26	12.4%
TOTAL	7	33	44	46	58	21	209	100%

*Four cases excluded because of stage classification performed after initial multimodality therapy

#4 Rectal Cancer, 2021

INCIDENCE OF RECTAL CANCER BY AGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-100	TOTAL
(N)	1	0	6	13	13	20	6	1	60

RECTAL CANCER TREATMENT BY AJCC STAGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

TREATMENT	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	LVHN TOTAL*	LVHN %
SURGERY ALONE	2	8	0	2	0	3	15	28.3%
SURGERY + CHEMOTHERAPY + RADIATION THERAPY	0	1	4	5	1	0	11	20.8%
CHEMOTHERAPY + RADIATION THERAPY	0	0	6	3	1	0	10	18.9%
CHEMOTHERAPY ALONE	0	0	1	1	2	0	4	7.5%
SURGERY + CHEMOTHERAPY	0	0	0	3	0	0	3	5.7%
RADIATION ALONE	0	0	1	0	1	0	2	3.8%
SURGERY + IMMUNOTHERAPY	0	0	0	0	1	0	1	1.9%
IMMUNOTHERAPY ALONE	0	0	0	0	1	0	1	1.9%
CHEMOTHERAPY + IMMUNOTHERAPY	0	0	0	0	1	0	1	1.9%
NO FIRST-COURSE TREATMENT	0	0	0	0	2	3	5	9.4%
TOTAL	2	9	12	14	10	6	53	100%

*Seven cases excluded because of stage classification performed after initial multimodality therapy

#5 Blood and Bone Marrow Cancer, 2021

INCIDENCE OF BLOOD AND BONE MARROW CANCER BY AGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

AGE AT DIAGNOSIS	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80-89	90-99	100-109	TOTAL
(N)	14	2	3	3	16	22	43	69	34	11	1	218

BLOOD AND BONE MARROW CANCER TREATMENT BY AJCC STAGE AT DIAGNOSIS: LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS AND LVHN-COORDINATED HEALTH

TREATMENT	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	STAGE NA	LVHN TOTAL	LVHN %
CHEMOTHERAPY ALONE	0	0	0	4	0	67	71	32.6%
CHEMOTHERAPY + HORMONE + IMMUNOTHERAPY	0	2	2	0	0	20	24	11.0%
OTHER THERAPY	0	0	0	0	0	11	11	5.0%
CHEMOTHERAPY + IMMUNOTHERAPY	0	0	0	0	0	7	7	3.2%
CHEMOTHERAPY + RADIATION + HORMONE + IMMUNOTHERAPY	0	0	0	0	0	6	6	2.8%
CHEMOTHERAPY + HORMONE THERAPY	0	0	0	0	0	6	6	2.8%
CHEMOTHERAPY + HORMONE + IMMUNOTHERAPY + TRANSPLANT	1	1	0	0	0	3	5	2.3%
CHEMOTHERAPY + STEM CELL TRANSPLANT	0	0	0	0	0	4	4	1.8%
TRANSPLANT ALONE	0	0	0	0	0	2	2	0.9%
RADIATION ALONE	0	0	0	0	0	2	2	0.9%
CHEMOTHERAPY + RADIATION + HORMONE + IMMUNOTHERAPY + TRANSPLANT	0	0	0	0	0	2	2	0.9%
CHEMOTHERAPY + IMMUNOTHERAPY + TRANSPLANT	0	0	0	0	0	1	1	0.5%
CHEMOTHERAPY + RADIATION THERAPY	0	0	0	0	0	1	1	0.5%
IMMUNOTHERAPY ALONE	0	0	0	0	0	1	1	0.5%
RADIATION + IMMUNOTHERAPY	0	0	0	0	0	1	1	0.5%
NO FIRST-COURSE TREATMENT	0	0	0	15	7	52	74	33.9%
TOTAL	1	3	2	19	7	186	218	100%



Suresh Nair, MD, Appointed Chair of American Board of Internal Medicine's Medical Oncology Board

Suresh Nair, MD, Physician in Chief of Lehigh Valley Topper Cancer Institute, was appointed to the American Board of Internal Medicine's (ABIM) Council as Chair of its Medical Oncology Board.

"I am honored to take on this role and I look forward to working with national leaders in research, education and standard-setting to ensure our specialty's board-certification requirements are reflective of the ever-evolving nature of the medical oncology field," Dr. Nair says.

Founded in 1936, the ABIM is a physician-led evaluation organization dedicated to establishing standards for physicians specializing in internal medicine and 21 subspecialties. The organization certifies nearly one in four physicians across the country, with more than 200,000 physicians board-certified in internal medicine and related specialties through ABIM.

As a member of the ABIM Council, Dr. Nair also will help oversee certification requirements that are fundamental across all medical specialties.

Dr. Nair has more than 32 years of medical oncology expertise and has worked at Lehigh Valley Topper Cancer Institute for more than 18 years. He was instrumental in starting the Cancer Institute's Hematology Oncology Fellowship Program. He also leads its membership in the Memorial Sloan Kettering Cancer Alliance, which expands the Cancer Institute's ability to offer premier cancer treatment and clinical trials to people throughout our region.



Hematologist oncologist Ranju Gupta, MD, patient Janice Stoudnour, Saxton, Pa., and cardiologist Deborah Sundlof, DO.

Lehigh Valley Health Network Cardio-Oncology Program Recognized as Global Center of Excellence

GOLD DESIGNATION FROM INTERNATIONAL CARDIO-ONCOLOGY SOCIETY APPLIES TO JUST 22 LOCATIONS IN THE U.S.

Lehigh Valley Heart and Vascular Institute's comprehensive cardiovascular program for cancer patients and survivors, now in its eighth year, has been recognized as a global center of excellence by the International Cardio-Oncology Society (IC-OS).

The cardio-oncology program was launched in 2015 by Heart and Vascular Institute cardiologist Deborah Sundlof, DO, and Lehigh Valley Topper Cancer Institute hematologist oncologist Ranju Gupta, MD. Both are cardio-oncology program co-directors.

The Heart and Vascular Institute's program received a gold center of excellence rating from IC-OS, the highest level awarded by the society. Just 31 hospitals or health systems in the world have gold ratings, including 22 in the U.S. Lehigh Valley Health Network is one of only two IC-OS gold centers of excellence in Pennsylvania.

Certain cancer treatments can cause cardiotoxicity, a condition that can weaken heart muscle, raise blood pressure or cause the heart to beat out of sync, the last a condition known as arrhythmia. Heart specialists in the cardio-oncology program assess a patient's heart disease risk and work with the patient's oncologist to develop a personalized treatment plan. The goal is to minimize or prevent heart-related problems because of cancer treatments.

Since its inception, the Lehigh Valley Heart and Vascular Institute's cardio-oncology program has served more than 650 patients and has become a major initiative, according to Dr. Sundlof, who also serves as co-director of the Heart and Vascular Institute's Women's Heart Program.

Lehigh Valley Hospital–Dickson City Opens

HOSPITAL CAMPUS INCLUDES ER, SURGICAL SUITES AND HEALTH CENTER

On May 19, Lehigh Valley Health Network opened Lehigh Valley Hospital (LVH)–Dickson City, bringing world-class, compassionate care to the Lackawanna County community.

The campus on Main Street includes a 100,000-square-foot state-of-the-art hospital with an extensive range of patient care and advanced diagnostic testing and a previously opened health center. The hospital has a surgical-specialty focus with seven operating rooms and two procedure rooms.

The community also will have access to premier emergency care with a 19-bay emergency room and a helipad for times when a higher level of care is needed.

LVH–Dickson City was built with patient comfort top of mind and features 24 private inpatient rooms.

SERVICES AT LVH-DICKSON CITY INCLUDE:

Unmatched surgical expertise – Lehigh Valley Institute for Surgical Excellence is known for its expertise in less-invasive techniques and robotic technology. Surgical and procedural programs offered at the campus include spine, joint replacement, general orthopedic surgery, hand surgery, general surgery, ear, nose and throat, urology, bariatric surgery and gastrointestinal surgery.

Advanced imaging – From computed tomography to ultrasound, X-ray and fluoroscopy, advanced imaging is in one convenient location.

24/7 emergency room – The 19-bay emergency room is equipped to provide care for everything from minor issues to more complex problems, all while providing an exceptional patient experience.

Telemedicine technology – Our secure virtual-care technology means all specialists in our health network are at your fingertips.

Private inpatient rooms – All inpatient rooms are private for added comfort.





LVPG–Delta Medix, Together With LVH–Dickson City, Brings Comprehensive Care to Scranton Area

A NEW HOSPITAL IN DICKSON CITY CATERS TO EVERY SURGICAL NEED, INCLUDING MINIMALLY INVASIVE AND ROBOTIC PROCEDURES

Delta Medix, the premier multispecialty practice in the Scranton area, joined forces with Lehigh Valley Physician Group (LVPG). Now known as LVPG–Delta Medix, the practice provides an unmatched range of exceptional health care services to Northeast Pennsylvania.

The acquisition of Delta Medix allows LVPG to expand into a very well-run and highly regarded multispecialty practice. As part of Lehigh Valley Health Network (LVHN), LVPG provides additional services, specialists and ancillary resources.

The 2022 opening of Lehigh Valley Hospital (LVH)–Dickson City highlights the benefits of this union. The new, state-of-the-art facility offers a wide array of patient care and diagnostic testing services. The hospital has a particular focus on surgical care, with seven operating rooms, two procedure rooms and advanced robotic technology. There was already a large surgery-component to Delta Medix, and joining LVPG allows it to continue to provide outstanding surgical care – but now across a larger breadth of services with a deeper bench of physicians and other clinicians.

Procedures offered at LVH–Dickson City include:

- Spinal surgery
- Joint replacement
- General orthopedic surgery
- Hand surgery
- Otolaryngologic surgery
- Urologic surgery
- Bariatric surgery
- Gastrointestinal surgery
- Hernia repair
- General surgery

The integration of Delta Medix into LVPG not only enables the new practice to sustain and grow these services, it also will help recruit quality surgeons to the area and replenish the surgical workforce.

READY ACCESS TO LVHN RESOURCES

For Delta Medix clinicians and patients, the move to LVPG facilitates access to:

- Lehigh Valley Topper Cancer Institute, which offers top-of-the-line cancer care and clinical trials, enhanced by membership in the prestigious Memorial Sloan Kettering Cancer Alliance.
- Lehigh Valley Institute for Surgical Excellence, which focuses on innovative, minimally invasive procedures, including a robotic surgery program that has grown into one of the busiest in the nation.
- Lehigh Valley Heart and Vascular Institute, which boasts the region’s most experienced heart and vascular teams, as well as specialized programs in women’s heart health, sports cardiology and more.

LVHN Opens LVH–Hecktown Oaks Phase 3

EXPANSION PROJECT INCLUDES STATE-OF-THE-ART INTENSIVE CARE UNIT AND HEALING GARDEN

Lehigh Valley Health Network (LVHN) celebrated the completion of its Lehigh Valley Hospital (LVH)–Hecktown Oaks Phase 3 construction project with a ribbon-cutting and tour. The expansion in Lower Nazareth Township, which includes an intensive care unit (ICU) for patients 18 and older and a healing garden, complements the already existing hospital that opened in June 2021.

The new state-of-the-art intensive care unit includes eight ICU beds and 12 progressive beds that allow physicians to triage patients before moving them. The ICU beds are located in private rooms with bathrooms. Each room features a 55-inch TV with 24/7 telemedicine capabilities.

Safety continues to be a priority at LVH–Hecktown Oaks. Throughout the ICU are strategically placed Indigo-Clean lighting and HEPA filters, as well as UV lights within the rooftop HVAC system, to control and eliminate bacteria.

“The health and safety of our community were at the forefront of the design of the ICU at LVH–Hecktown Oaks,” says David Burmeister, DO, Chair, Emergency and Hospital Medicine, LVHN. “In the event that you or a loved one needs emergency care or requires high-level care in the intensive care unit, you will be in good hands at LVH–Hecktown Oaks.”

The expansion also features a healing garden that was built thanks to the generosity of the John and Margaret Post Foundation. The healing garden will provide a space for quiet meditation and reflection for patients and visitors. Windows within the infusion bay, as well as in some inpatient rooms, were designed so that patients would be able to view the healing garden.

Additional services provided at LVH–Hecktown Oaks include:

- **Cancer services** through Lehigh Valley Topper Cancer Institute, which is part of the Memorial Sloan Kettering Cancer Alliance.
- **Breast Health Services.**
- **A Diagnostic Care Center** with imaging services, lab medicine and cardiac diagnostics, including the Multitom Rax precision X-ray technology. This technology is the only one in the region and limits unnecessary radiation while allowing for easy scanning of the patient to avoid excessive movement if in pain or because of limited mobility.
- **Four state-of-the-art surgical suites** for procedures with Lehigh Valley Institute for Surgical Excellence experts, including use of the latest-generation da Vinci Robotic System.
- **A 24/7 emergency room** with a dedicated space just for kids.
- **Private inpatient rooms**, each with private bathrooms, telehealth capabilities and a 55-inch flat-screen TV.
- **Lehigh Valley Heart and Vascular Institute** cardiology and cardiac diagnostics.
- **Complete bone, joint, spine and sports medicine care** with Lehigh Valley Orthopedic Institute.
- **Outpatient rehab.**
- **Family medicine.**





Expanded Cancer Services at New Carbon County Hospital

CANCER PROGRAM BLENDS CLINICAL EXCELLENCE WITH CLOSE-TO-HOME CONVENIENCE

The new Lehigh Valley Hospital (LVH)-Carbon campus, along Route 443 just outside Lehighton, now boasts a location of Lehigh Valley Topper Cancer Institute. The Cancer Institute is the only cancer center in the region that is part of the prestigious Memorial Sloan Kettering (MSK) Cancer Alliance.

For people in the area, the cancer program at LVH-Carbon will offer convenient access to an array of cancer services and an experienced hematology oncology team.

LESS DRIVING, MORE THRIVING

Lehigh Valley Health Network (LVHN) had already established a reputation for first-rate oncology care among Carbon County residents. In the past, however, cancer patients and caregivers had to drive to LVH-Cedar Crest near Allentown for many diagnostic and treatment services. Now, thanks to the expanded program at LVH-Carbon, the commute for cancer care in many cases is much shorter.

Services such as infusion and imaging are on-site. That is great news for the entire community, and it may be a particular advantage for older patients, who often find it difficult to travel longer distances.

HIGH-QUALITY ONCOLOGY CARE

Patients at LVH-Carbon now benefit from the same compassionate care and clinical expertise that they have come to expect from all Cancer Institute locations.

Among the hematology oncology services available at the LVH-Carbon campus:

- Infusion treatments, including chemotherapy, immunotherapy, hydration therapy and blood transfusions.
- Phlebotomy services, including blood draws for benign hematologic conditions.
- Advanced imaging, including computed tomography, MRI and ultrasound capability.
- Virtual consults with the Cancer Institute's large network of multidisciplinary cancer specialists, including surgical oncologists and radiation oncologists.
- Genetic counseling to help people make informed decisions about their health.

As a member of the MSK Cancer Alliance, the Cancer Institute also provides access to world-class clinical trials. Cancer patients at LVH-Carbon will be screened for trials offered at other Cancer Institute locations.



Comprehensive Cancer Center Coming to LVH–Hazleton

THE CENTER WILL HOUSE EXPANDED STATE-OF-THE-ART CANCER SERVICES AT ONE CONVENIENT LOCATION

Lehigh Valley Health Network (LVHN) made a commitment when it first moved into Hazleton: It would bring quality health care to residents in their own community.

LVHN is keeping this commitment in a big way with the building that is now going up on the Lehigh Valley Hospital (LVH)–Hazleton campus. This three-story, 32,000-square-foot facility will house the new Lehigh Valley Hospital–Hazleton Cancer Center.

Once the center opens in summer 2023, people will be able to receive all their cancer care in the same building. That includes doctor’s appointments, infusion and radiation treatments and support-group meetings. Now, some of these services are spread throughout the community, requiring a visit to a clinic off the hospital campus or even traveling to Allentown.

“Travel can be challenging for patients who are dealing with cancer and those supporting them through their treatment plan,” says Melissa Curto, Vice President, Patient Care Operations, at LVH–Hazleton. “For example, a patient receiving chemotherapy may be there for several hours and not feel well afterward. Less time traveling allows more healing time for the patient and doesn’t impact their loved ones’ work and home schedule as much, which is so important in this journey they are in together.”

“This gives patients in Hazleton and neighboring communities every chance for another lifesaving measure.”

WIDE ARRAY OF CANCER SERVICES

The LVH–Hazleton Cancer Center will be part of Lehigh Valley Topper Cancer Institute. That means people will benefit from access to top cancer-doctors, leading-edge cancer treatments and groundbreaking clinical trials. Here’s a glance at what the cancer center will offer:

Advanced technology for radiation therapy. In terms of technology, the crown jewel of the center is a linear accelerator with computed tomography simulation. This system delivers sophisticated image-guided radiation therapy. It precisely targets tumors while sparing nearby healthy tissue.

Infusion suite. Some cancer therapies, such as chemotherapy, may be given in a series of infusions (intravenous treatments). The cancer center will have 14 private infusion rooms with TVs and other amenities for comfort. “Plus, the infusion suite will be on the third floor, where patients will have beautiful views of the Hazleton area,” Curto says. “This was an important component when designing the center. The path to healing requires a positive physical, mental and emotional experience during each step of the course of care.”

Medical oncology. A team of highly regarded cancer physicians from Lehigh Valley Physician Group Hematology Oncology is currently based about five miles from the hospital. When the cancer center opens, the medical practice will relocate to this new, easy-to-access facility.

Session suite. Some patients need very specialized care, such as the kind of care provided by gynecologic oncologists and cancer surgeons. The cancer center will have additional exam rooms for use by visiting LVHN cancer specialists who travel to Hazleton to see patients.

Telehealth capabilities. What if a specialist is unable to go to Hazleton? Individuals will be able to connect with that doctor via telemedicine. That means they can tap into the expertise of cancer specialists throughout LVHN without having to travel.

Clinical trials. People who have exhausted traditional treatment routes will have expanded access to next-level clinical trials. “This gives patients in Hazleton and neighboring communities every chance for another lifesaving measure,” Curto says.

CLINICAL TRIALS

Cancer research is at the forefront at Lehigh Valley Topper Cancer Institute. Clinical trials benefit patients because they provide access and hope to new ways in the diagnosis, prevention, treatment and cure of cancer. We bring the latest and most innovative clinical trials closer to home for our patients. Together with our alliance with Memorial Sloan Kettering, we offer a wide range of clinical trials that offers opportunities for the latest and innovative treatments while ensuring patient safety.

TRIALS	ADULTS	PEDS	TOTAL
PHASE I	3	1	4
PHASE II	33	12	45
PHASE III	27	13	40
EXPANDED ACCESS	2	0	2
REGISTRY	5	4	9
REGISTRY/BIOLOGY	0	1	1
BIOLOGY	4	2	6
TOTAL	74	33	107





Detecting Earliest Signs of Cancer Recurrence

STRATA SENTINEL TRIAL OFFERS CUSTOM-DESIGNED GENOMIC MONITORING

Patients at Lehigh Valley Topper Cancer Institute have access to an innovative clinical trial that will help advance the ability to detect cancer recurrence in its earliest stages and monitor treatment effectiveness. The Strata Sentinel trial will enroll people with stage 1, 2 and 3 solid tumors who have completed or are planning to undergo curative surgery or definitive cancer therapy.

Strata Oncology will use tumor and blood samples from these individuals to create a personalized genomic profile of the tumor tissue and design a StrataMRD (minimal residual disease) test targeting specific mutations.

Individuals will then have blood draws every three months to search for circulating tumor DNA. This is the first time that the StrataMRD test will be used to monitor people who have had solid tumors.

SECOND SITE IN THE NATION

The Cancer Institute will be only the second site in the U.S. to enroll people in the trial, which is expected to include 20,000 people who will be followed for up to five years.

Almost every solid-tumor type except for brain tumors may be included in the trial; the hope is to enroll at least **50** Lehigh Valley Health Network (LVHN) patients.

ONGOING PARTNERSHIP

The Sentinel trial is LVHN's second collaboration with Strata Oncology, a genomic testing and precision medicine company based in Ann Arbor, Mich. 711 people have signed consent for the initial Strata trial, with 672 people receiving results.

Individuals enrolled in the Sentinel trial may benefit in several ways, whether or not they elect to know the results of their blood tests, and whether or not their cancer recurs. Physicians tend to underestimate the risk of recurrence, but patients are more realistic. Being closely monitored with ongoing genomic testing may provide a lot of reassurance. Depending on the results, physicians may choose to change imaging or treatment protocols.

The specificity of the testing also allows for mutations to be detected via a blood sample, which could lead to options for targeted therapy for patients as well.

In future trials, we may be able to get quantitative measures of the amount of circulating tumor DNA to see if it is increasing over time. Eventually, the hope is to be able to map treatments to a patient's specific tumor profile. This is a very ambitious project, and Lehigh Valley Topper Cancer Institute is well poised to maximize its potential.

Memorial Sloan Kettering Alliance Takes Cancer Research to a Higher Level – With Suresh Nair, MD

In January 2022, President Joe Biden announced plans to reignite the Cancer Moonshot, setting the ambitious goal of reducing the cancer death rate by 50% over the next 25 years.

Through genomic testing, precision oncology and immunotherapy, the goal is reachable at Lehigh Valley Health Network, says Suresh Nair, MD, Physician in Chief at the network's Lehigh Valley Topper Cancer Institute, in an interview with Healthcare Finance News.

AMONG THE REASONS WHY THE GOAL IS ATTAINABLE:

- Innovations include strong robotic-surgery programs for less-invasive treatments and faster recovery.
- The Cancer Institute's alliance with Memorial Sloan Kettering reduces the delay between cancer research and care thanks to advancements in technology.
- The Cancer Institute is participating in clinical trials on the molecular profiling of tumors. This is a real-time tumor tracking system.
- Genomic testing, precision medicine and immunotherapy will help reach the goal of the Cancer Moonshot to reduce the cancer death rate by 50% over the next 25 years.
- The combined expertise of multidisciplinary teams in cancer treatment can leverage new research and clinical trials, sometimes years ahead of other cancer research and treatment.
- The alliance allows for the rapid deployment of increased standards of care – in real time – as new research becomes available.

Cancer Risk and Genetic Assessment Program

Cancer can happen to anyone. But some people face a higher risk for certain cancers because of genetic abnormalities that are passed down in families (hereditary cancer). Cancer genetics experts at Lehigh Valley Topper Cancer Institute help patients and their families learn more about their risk and what we can do to preserve their well-being.

The Gregory and Lorraine Harper Cancer Risk and Genetic Assessment Program of the Cancer Institute is one of the few programs in the region offering the complete range of cancer genetics services, including cancer risk and genetic assessments. Our genetic counselors provide personalized recommendations to help you know your risk for cancer. For those already diagnosed with cancer, we partner with patients and their physicians regarding treatment decisions.

Cancer genetics services include:

Genetic counseling: Our board-certified genetic counselors specialize in cancer genetics. We explain the risk for hereditary cancer and help you determine whether genetic testing is right for a patient.

Cancer risk assessments: Our genetic counselors ask questions about a patient's individual and family health history to determine their risk for hereditary cancer. We explain which cancers for which they may be at risk and how likely it is for these cancers to develop.

Genetic testing: Using a sample of a patient's blood, we check for problems in their genes (mutations) that may cause hereditary cancer.

FY 2022



CURRENT INITIATIVES

- Expanding the genetics follow-up clinic to the Lehigh Valley Hospital (LVH)–Hecktown Oaks location, in addition to LVH–Cedar Crest, to provide ongoing care for people at high risk of cancer because of a hereditary cancer syndrome.
- Collaborating with Breast Health Services, gynecology physicians and clinicians and primary care physicians and clinicians to improve identification of individuals who may be at risk for a hereditary cancer syndrome and to provide up-to-date educational resources for patients and clinicians.
- Presently we have five full-time certified genetic counselors, a nurse practitioner, a medical director, a genetic counseling assistant and an outreach coordinator. Genetic counseling services are now offered at four locations: LVH–Cedar Crest, LVH–Muhlenberg, LVH–Hecktown Oaks and LVH–Pocono.




Radiation Oncology

Lehigh Valley Topper Cancer Institute's radiation oncology department is committed to delivering high-quality cancer care through personalized and innovative treatment regimens. We utilize state-of-the-art equipment to offer advanced treatment techniques, including the Lehigh Valley's only Gamma Knife® Icon™ radiosurgery unit.

SERVICES PROVIDED

- Stereotactic body radiotherapy
- Leksell Gamma Knife Icon
- Real-time tumor tracking with Calypso
- Surface-guided radiotherapy with AlignRT
- Respiratory gating
- SpaceOAR™ hydrogel for prostate treatment
- Personalized 3D-printed treatment devices

FY 2022



Gamma Knife® Icon™ Procedure Provides Safe, Effective Radiation Therapy

TREATING TUMORS, VASCULAR ABNORMALITIES AND MORE

Lehigh Valley Health Network (LVHN) long has been committed to leadership in neuro-oncology, neurosurgery and radiation oncology. This commitment is evident in the ongoing management of the region's only Gamma Knife Icon unit, which allows LVHN's experienced neurosurgeons and radiation oncologists to treat a variety of benign and malignant conditions in a single outpatient procedure.

The Gamma Knife has been in place at Lehigh Valley Hospital-Cedar Crest since 2004, part of Lehigh Valley Topper Cancer Institute. About **2,000** Gamma Knife procedures have been performed since the program started in 2004, and current volumes are around 150 cases annually. All physicians who use LVHN's Gamma Knife have received special training and are certified in its use.

Gamma Knife is the noninvasive gold standard for treating both malignant and benign conditions of the brain and upper spine.

GOLD STANDARD

Gamma Knife is the noninvasive gold standard for treating both malignant and benign conditions of the brain and upper spine that otherwise are difficult to safely treat. It is very effective compared to other modalities and less time-consuming, offering significant advantages for metastases and other tumors.

In development since the 1950s, the Gamma Knife came into use in clinical practice in the late 1980s. However, the Gamma Knife came into broader use in the 1990s, after integration with the computer. Gamma Knife is the most precise form of radiation therapy for intracranial targets. Such precision allows us to treat lesions with minimal risk to surrounding normal structures.

Among the most important advances in recent years has been the added capability to treat most patients without employing the head frame to the skull, used for immobilization of the head during treatment. While only minimally invasive, placement of the head frame may add to patient stress and cause temporary discomfort.

Following the Gamma Knife Icon upgrade, most patients are treated using a custom-fit thermoplastic mask that holds the head securely in place during treatment. The addition of a computed tomography scanner and an optical tracking system to the Gamma Knife makes the use of the frameless approach possible.

TREATING A RANGE OF CONDITIONS

Conditions that can be treated with the Gamma Knife include acoustic neuromas, pituitary adenomas, pinealomas, craniopharyngiomas, meningiomas, chordomas, brain metastases, glial tumors, arteriovenous malformations and a variety of functional disorders including trigeminal neuralgia. LVHN also offers stereotactic radiosurgery with the Varian Edge linear accelerator for conditions not suitable for treatment with Gamma Knife.

Breast Health Services

FY 2022

103,336
Total mammograms*

96,797
Total 3D mammograms*

8,963
Total call-backs for all sites*
(including mammo coach)

*Includes all mammograms, all sites

Breast Health Services at Lehigh Valley Topper Cancer Institute is committed to offering world-class breast care for women of all stages of life. We offer access to screening and diagnostic services at many breast health centers across the region.

We use the latest advanced-imaging technologies, such as 3D mammography, to detect breast cancer and other breast conditions in the earliest, most treatable stage. For women who experience breast cancer, you can expect innovative cancer care at Lehigh Valley Topper Cancer Institute.

EXCEPTIONAL QUALITY

Lehigh Valley Health Network Breast Health Services is an American College of Radiology-accredited Center of Excellence. We hold accreditation in many essential programs, which is a testament to the outstanding quality we provide to every woman under our care.

EXPERIENCE

Our board-certified radiologists exceed the national average for finding cancer at its earliest stage. They read more than twice as many mammograms as the Food and Drug Administration (FDA) requires, a volume that leads to an uncommon level of precision.

ADVANCED TECHNOLOGY

Detecting breast cancer as early as possible is our mission. Tomosynthesis, also known as 3D mammography, makes possible the diagnosis of hidden breast cancer.

During 3D mammography, an arc of X-ray images is taken of each breast. The images are reconstructed into a three-dimensional image. This allows the radiologist to evaluate the breast layer by layer, helping to distinguish a true mass from overlapping tissue, as well as helping to detect smaller lesions that may be hidden on a conventional 2D mammogram.

3D mammography is the only mammogram FDA-approved as superior for women with dense breasts.



CONVENIENCE ON LAND AND ON WHEELS

You have access to the most advanced breast screening technology available at LVHN breast health centers across the region. Several locations offer walk-in care.

For even more convenience, our mobile mammography coach provides a convenient way for you to receive a 3D screening mammogram. This is the same imaging technology we use at our hospitals, and it is provided by our outstanding Breast Health Services technicians who have specialized in breast mammography.

WORLD-CLASS CARE

The Cancer Institute is a Certified Quality Breast Center of Excellence with the National Quality Measures for Breast Centers™ Program administered by the National Consortium of Breast Centers.

This voluntary program focuses on the tracking and sharing of quality measures, such as patient satisfaction and timeliness of imaging care, as well as complication rates. We provide each patient with the highest quality of care through shared learning.

FY 2022

74

Mobile mammo coach number of locations served

2,075

Mobile mammo coach total number of patients screened




Infusion Services

Infusion therapy involves the delivery of fluids, including cancer drugs such as chemotherapy, immunotherapy, targeted therapy and antibiotics, as well as blood transfusion and other medications for infusion or injection.

At Lehigh Valley Topper Cancer Institute, we have specially trained nurses and pharmacists who help patients to have a safe experience – genuinely caring about restoring patients’ sense of wellness. The team assists in making it easy for patients to receive infusions on schedules that work for them and does everything to make sure that they receive the care to meet each patient’s unique needs.

FY 2022 visits



38 infusion bays at LVH-Cedar Crest, John and Dorothy Morgan Cancer Center at Tom and Karin Hall Center for Infusion and Cellular Therapies

24 infusion bays at LVH-Muhlenberg

12 infusion bays at LVH-Hecktown Oaks



The newest Lehigh Valley Health Network infusion center opened at Lehigh Valley Hospital-Carbon on June 8. The infusion area has eight bays and offers a convenient state-of-the-art-facility for the Carbon County population. It had **105** visits in the first month.





Lehigh Valley Topper Cancer Institute Utilizes Point-of-Care Ultrasound

EMERGENCY MEDICINE AND ONCOLOGY CLINICIANS TEAMED UP TO MAKE INTRAVENOUS LINE INSERTIONS EASIER FOR CANCER PATIENTS

When Lehigh Valley Topper Cancer Institute was gifted a point-of-care ultrasound (POCUS) as part of a generous donation from Tom and Karin Hall, there was a lot of excitement. POCUS helps clinicians find veins more easily when putting in intravenous (IV) lines, which reduces insertion attempts. This ultimately leads to higher patient satisfaction and fewer complications (such as infections and blood clots).

However, there was one problem: none of the Cancer Institute nurses were trained to use it.

TEAMING UP

Jill Korn, RN, knew she had to address this problem. She is Director of Clinical Services for the Tom and Karin Hall Center for Infusion and Cellular Therapies at Lehigh Valley Topper Cancer Institute at Lehigh Valley Hospital (LVH)–Cedar Crest.

She was aware that POCUS has been used in Lehigh Valley Health Network (LVHN) emergency rooms for a long time. So she contacted emergency medicine physician Kevin Roth, DO, with the Emergency Room at LVH–Muhlenberg and the Emergency Room at LVH–Cedar Crest.

Dr. Roth quickly set up a lecture and hands-on tutorial for oncology nurses. Afterward, the nurses began proctored patient-training to become even more skilled with the technology.

More oncology nurses are expected to train on POCUS with the support of experienced emergency medicine nurses. And as members of the first cohort complete their proctored patient training (by performing 25 successful IV line placements), the nurses will begin to use the technology independently in the Cancer Institute's treatment areas.

Lehigh Valley Reilly Children's Hospital

Pediatric cancer is a complex disease, but cancer treatment options are always advancing. Experts at Lehigh Valley Reilly Children's Hospital are here to help. Our team has decades of combined experience treating a wide range of pediatric cancers with excellent results.

When you choose Children's Hospital for cancer care, your child will benefit from our:

WORLD-CLASS TREATMENTS

Our pediatric hematology oncology program is part of the Children's Oncology Group (COG), the largest international consortium of pediatric cancer hospitals and clinicians. This association means we care for patients using the same protocols that the world's foremost cancer centers follow.

PEDIATRIC EXPERTISE

Lehigh Valley Reilly Children's Hospital is the region's only institutional member of the Children's Hospital Association. It is also home to the area's only board-certified pediatric specialists in cancer care and other specialties. Our entire team of experts in more than 30 pediatric subspecialties has a passion for providing the highest-quality care for our smallest patients. All of our experts are available to assist in the care of patients with cancer.

TEAM APPROACH

When you come to Lehigh Valley Reilly Children's Hospital for cancer care, multiple specialists will weigh in on your child's care. This approach helps ensure a treatment plan is tailored to your child's needs. Your care team may include:

Pediatric hematologist oncologist – This doctor specializes in treating blood disorders and cancer in children. Our doctors are fellowship trained in pediatric hematology oncology.

Pediatric surgeon – This doctor is skilled in surgery and cares for children who may have surgical needs as part of their cancer care. Our pediatric surgeons are fellowship trained in pediatric surgery specialties.

Pediatric oncology-certified nurses – Many of our registered nurses have earned specialty certification in pediatric hematology oncology and are knowledgeable, compassionate partners in your child's medical care.

Radiation oncologist – This doctor specializes in using radiation to treat cancer.

Pediatric anesthesiologist – This doctor administers medicine during surgery to help infants, children and adolescents relax and fall asleep. Our pediatric anesthesiologists are all fellowship trained in the use of anesthesia with young patients and are the only team of pediatric anesthesiologists in the area.

Pediatric radiologist – This doctor uses a variety of imaging technologies, such as X-ray, computed tomography scan, MRI, ultrasound and other imaging techniques to diagnose diseases and injuries in infants, children and adolescents. Our pediatric radiologists are all fellowship trained in pediatric radiology.

Supportive care specialists – Our team of supportive care specialists, such as our child-life specialists and physical therapists, is here to help your child manage coping with a serious illness.





CHILD-LIFE PROGRAM

Certified child-life specialists help kids cope with a visit to the hospital. They are experts in child development and partner with doctors, nurses, social workers and other members of your care team to meet the unique needs of your child and your family.

The child-life program at Lehigh Valley Reilly Children's Hospital is the only one in the area where child-life specialists help children receiving medical treatment by offering opportunities for stress relief and relaxation, as well as distractions to make procedures easier.

LATEST THERAPIES

Medical research helps advance therapies for rare diseases. Because we're a member of COG, we can participate in dozens of clinical trials that explore promising treatments for pediatric cancer. This focus on research helps ensure every patient in our care gets the latest and best treatment.

MORE CANCER SERVICES IN ONE PLACE

You can access leading cancer treatments in a kid-friendly space at Children's Cancer and Multipurpose Infusion Center at Lehigh Valley Reilly Children's Hospital. The center is located close to our:

- Cancer specialists
- Pediatric inpatient unit
- Radiation therapy services
- Imaging services
- Children's ER
- J.B. and Kathleen Reilly Children's Surgery Center

EXTENSIVE SUPPORT

Once cancer touches your life, you are forever changed. Our extensive support services help your child and your family manage the physical and emotional demands of cancer from diagnosis to life after treatment.



LVHN Hospitals Designated ‘Leaders’ in LGBTQ+ Healthcare Equality Index

THIS ACHIEVEMENT HIGHLIGHTS LVHN’S COMMITMENT TO INCLUSIVITY AND EQUALITY

Lehigh Valley Health Network (LVHN) hospitals are receiving national recognition for demonstrating a commitment to advancing health equity in the lesbian, gay, bisexual, transgender, queer or questioning (LGBTQ+) community.

The Human Rights Campaign (HRC) designated Lehigh Valley Hospital (LVH)–Cedar Crest, which includes LVH–17th Street and LVHN–Tilghman, LVH–Muhlenberg and LVH–Pocono, as Leaders in its LGBTQ+ Healthcare Equality Index (HEI).

“This designation highlights LVHN’s dedication to creating an inclusive environment for our patients and colleagues,” says Judith Sabino, Chief Diversity, Equity and Inclusion Liaison, LVHN. “We are proud to be recognized as national leaders who show our commitment to the LGBTQ+ community by providing equitable, high-quality health care and a workplace where everyone feels respected.”

HEI is a national benchmarking tool that evaluates health care facilities’ commitment to inclusion of and equity for their LGBTQ+ patients, visitors and employees. This is the third time LVHN submitted evidence to be considered for this HEI designation.

HEI evaluates and scores health care facilities on detailed criteria falling under four central pillars:

- Foundational policies and training in LGBTQ+ patient-centered care
- Employee benefits and policies
- LGBTQ+ patient services and support
- Patient and community engagement

“Lehigh Valley Health Network shows continuous commitment to LGBTQ+ community members in our area,” says Kimberly Levitt, DHS, Health Programs Manager, Bradbury-Sullivan LGBT Community Center. “Through our partnership, we have the ability to implement public health initiatives throughout the year. LVHN is truly a fundamental health leader, and Bradbury-Sullivan LGBT Community Center is proud to see this recognition from the Human Rights Campaign.”

In the 2022 report, 496 facilities earned HRC’s LGBTQ+ Healthcare Equality Index Leader designation. These facilities, including LVHN, received the maximum score in each section, with an overall score of 100.

Another 251 facilities earned the “Top Performer” designation with scores between 80 and 95 points and at least partial credit in each section.

With 82% of participating facilities scoring 80 points or more, health care facilities are demonstrating concretely that they are going beyond the basics when it comes to adopting policies and practices in LGBTQ+ care.

Multidisciplinary Cancer Case Conferences

The cancer data management department (cancer registry) organizes multidisciplinary cancer case conferences, also known as tumor boards. These are conferences involving multidisciplinary teams of physicians and other allied health professionals who discuss and evaluate cancer cases and make treatment decisions and recommendations. This process results in improved clinical decision-making, clinical outcomes and overall patient experience.

Tumor boards convene the multidisciplinary team of physicians and clinicians to engage in robust discussions and collaboration to evaluate and discuss treatment planning for our cancer patients. Aside from identifying treatment recommendations, elements of discussion include clinical and pathologic staging of each cancer case, options and eligibility for genetic testing, clinical research studies and supportive care where applicable.

Because of the COVID-19 pandemic, our multidisciplinary conferences transitioned to virtual meetings. This format improved and increased access to the meetings and enhanced participation from colleagues from all Lehigh Valley Health Network campuses, which benefits our patients even more.

SITE-SPECIFIC SPECIALTY MULTIDISCIPLINARY CANCER CASE CONFERENCES:

- Adolescent and young adult
- Breast
- Colon/rectal
- Rectal
- Ear, nose and throat
- Endocrine
- Combined/general
- Gynecologic oncology
- Heme-lymphoma
- Hepatobiliary and upper gastrointestinal
- Neuro-oncology
- Pediatric oncology
- Pulmonary
- Skin and soft tissue
- Urology

FY 2022

15

Site-specific specialty tumor boards

280

Total number of cancer conferences held

1,534

Total number of cases presented

10,814

Total attendance



Multidisciplinary Clinics and Patient Navigation

The Oncology Navigation and Social Work team has shown significant growth during FY 2022. With the opening of Lehigh Valley Hospital-Hecktown Oaks, our navigation and social work services were extended to more patients who have been able to benefit from the knowledge and resources that our team has to offer. As a result of extending our services and an increase in utilization by our physicians and other clinicians, social work referrals and patient encounters have increased by nearly 50% in FY 2022.

Multidisciplinary clinic (MDC)* total visits – 422

Thoracic	104
Breast	137
Genitourinary	30
Upper gastrointestinal tract	44
Skin and soft tissue	40
Head and neck	21
Survivorship	46

** Multidisciplinary clinic (MDC) team includes doctors and advanced practice clinicians who know and understand your condition. They represent treatment specialties such as surgical oncology, medical oncology and radiation oncology. This team, as well as a nurse navigator, will explain any unfamiliar terms to you and help you understand your diagnosis and treatment options.*





Surgical Oncology Excellence in the Lehigh Valley

PATIENTS WITH GASTROINTESTINAL CANCER CAN ACCESS EXPERIENCED SURGEONS AND ADVANCED PROCEDURES WITHIN THEIR COMMUNITY

Successful patient outcomes are commonly linked to a surgical oncologist's surgical volume and overall expertise.

This is particularly true for patients with gastrointestinal (GI) malignancies.

"There's no replacement for volume and experience when it comes to treating GI cancers," says surgical oncologist Jeffrey Brodsky, MD, with LVPG Surgical Oncology. "While completing hundreds of complex oncologic procedures, I've developed advanced expertise with surgical techniques, anatomy and anatomical variants."


Dr. Brodsky and fellow surgical oncologist Aaron Blackham, MD, with LVPG Surgical Oncology, treat a full range of GI malignancies, including rarer conditions such as small bowel tumors, retroperitoneal sarcomas and carcinoids.

Working with specialized clinical staff, they offer a wide array of surgical treatment options not often seen in a community setting, such as the Whipple procedure, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and esophagogastrectomy.

These procedures are routinely performed at our Lehigh Valley Topper Cancer Institute. For some disease sites, our GI surgical oncology team is ranked among the top four in the state for surgical volumes between July 2019 and June 2020.

While some may look to academic centers in urban settings for this vast expertise, at Lehigh Valley Topper Cancer Institute, Brodsky and his colleagues have similar surgical volumes and offer many of the same advanced procedures, allowing patients to be treated closer to home.

"There is no replacement for volume and experience when it comes to treating GI cancers."



LVHN's Robotic Surgery Team Surpasses 25,000 Procedures

EMPLOYING TOP-TIER TECHNOLOGIES TO DELIVER OUTSTANDING CARE ACROSS 13 SURGICAL SPECIALTIES

Last year, Lehigh Valley Health Network (LVHN) celebrated a milestone: 25,000 surgeries performed by its robotic surgery team since 2008, when the program launched.

PRIORITIZING PATIENT OUTCOMES

The program has accelerated very quickly to the point where it rivals the best in the country. LVHN has helped thousands of individuals through robotic surgeries with fewer incisions, less blood-loss, less pain and less scarring, resulting in quality outcomes and a faster return to normal activity.

The Robotic Surgery Center for Excellence was created with the explicit reason of constantly improving our outcomes. Our continued investment in acquiring the latest surgical technologies shows our commitment to offering patients the best possible care.

NONSTOP GROWTH AND DEVELOPMENT

In the beginning, LVHN's robotic team focused primarily on urologic and gynecologic surgeries using the trailblazing da Vinci Surgical Systems. Surgical techniques have evolved along with the various da Vinci system iterations, the S, Si, HD, X and Xi. LVHN is one of the very few health systems to offer the SP (single port), which is used in delicate surgeries through a one-inch incision.

Today, the team consists of more than 100 robotic surgeons in:

- General surgery
- Urology
- Bariatric surgery
- Surgical oncology
- Spine
- Colorectal surgery
- Thoracic surgery
- Gynecologic oncology
- Urogynecology
- Orthopedic surgery
- Gynecology
- Ear, nose and throat
- Reproductive surgery

Introducing Lehigh Valley Fleming Neuroscience Institute

WE ARE FURTHER ADVANCING LEADING-EDGE NEUROLOGY AND NEUROSURGERY CARE

Lehigh Valley Health Network (LVHN) in 2022 created Lehigh Valley Fleming Neuroscience Institute to significantly expand the breadth and depth of its neurology and neurosurgery research, training and care in the region.

The Neuroscience Institute's creation was made possible by a significant gift from the Fleming Foundation, established by the late businessman and philanthropist Richard Fleming, a longtime chairman of LVHN's Board of Trustees. The gift is the largest single endowment in the Fleming Foundation's 32-year history.

LVHN annually serves about 32,000 neurology patients and about 18,000 neurosurgery patients, a number that has grown significantly in recent years. Establishing the Neuroscience Institute will allow LVHN to significantly expand its neuroscience team over the next several years as patient demand continues to escalate. Needs are great in all subspecialty areas of neurology.

32,000
Neurology
patients annually

18,000
Neurosurgery
patients annually



Cancer Program Annual Goal

Each calendar year, Lehigh Valley Topper Cancer Institute's cancer committee establishes a cancer program goal in compliance with the requirements of our accreditation with the Commission on Cancer.

For 2022, our cancer program goal was to develop a plan to implement advance care planning (ACP) in the Cancer Institute. An ACP proactively addresses an individual's health goals, values, preferences and resources in anticipation of future medical conditions and decision-making needs. An ACP ensures that a patient will receive the care that's right for them and what they desire.

This cancer program goal was successfully completed, and the following processes were established:

- Documentation for ACP to be pulled into the oncology encounters in our electronic health records (EHR).
- Education was provided to Lehigh Valley Topper Cancer Institute colleagues.
- Identification of areas to provide patient education, including waiting areas and examination rooms.
- Collaboration with EHR vendor to develop a report to measure ACP documentation for oncology patients.

Evidence-Based Study

The Lehigh Valley Topper Cancer Institute is a facility accredited by the Commission on Cancer. One of the program standards requires us to conduct an in-depth retrospective study of the diagnosis, evaluation and treatment of patients to determine concordance with evidence-based guidelines.

For 2022, our evidence-based study focused on patients diagnosed with cervical cancer from 2019 and later and reviewed in consistency with the National Comprehensive Cancer Network's 2022 guidelines for work-up and treatment.



Cancer Rehabilitation Services

Cancer rehabilitation programs often can improve function, reduce pain and improve the overall well-being of patients experiencing the challenges of a cancer-related diagnosis. LVHN Rehabilitation Services offers comprehensive care to patients in our communities throughout their cancer journey.

Many survivors of cancer experience lasting, adverse effects caused by either their disease or its treatment. Therapy interventions often can reverse or improve the impairments found in both new and existing patients with a cancer diagnosis and improve their ability to carry out daily tasks and participate in life situations. Patients who can be considered for rehabilitation referrals are those with lymphedema, cancer-related fatigue, range-of-motion deficits, functional strength and flexibility deficits, endurance deficits, swallowing deficits, memory loss/processing deficits and home-management deficits.

The rehabilitation team consists of board-certified clinical specialists – available to treat a wide variety of conditions – including physical therapists, occupational therapists, speech therapists and audiologist. Additionally, rehab services are available for inpatients and outpatients. For inpatient services, therapy is available seven days a week 365 days a year, and the order response is within 48 hours.

LVHN's Rehab Services can help a cancer patient overcome obstacles related to surgery or side effects from cancer treatment. The rehab team is always committed to pursuing its goal of helping patients improve their daily functions and quality of life.

Inpatient therapy services are available seven days a week, 365 days a year.



Palliative Care Services

Palliative care is specialized medical care for people with serious illness. This type of care focuses on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for the patient and family.

Palliative care is provided by a specially trained team of doctors, nurses and other specialists who work together with a patient's other doctors to provide an extra layer of support. It is appropriate at any age and at any stage in a serious illness, and it can be provided along with curative treatment.

Outcomes after critical illness and surgery (OACIS)/palliative medicine can assist with:

- Medical collaboration and management across the care continuum
- Clarifying goals of care and treatment
- Advance care planning
- Self-management goals
- Complex symptom management
- Complex communication
- Preventive care planning
- Communication and collaboration with oncologist and primary care physicians
- Exploring psychosocial and spiritual needs


Our services are provided in the hospital setting, the office or home. We offer in-person and telemedicine options to patients. We are there to help coordinate with your physician and members of your health care team to determine the kind of care you want.

Nutrition Counseling

Lehigh Valley Topper Cancer Institute offers patients access to registered dietitian nutritionists (RDNs) who are uniquely trained to assist patients and their families in managing treatment-related nutrition concerns. They can address patient needs and goals as well as provide strategies to achieve them before, during and after treatment.

Our RDNs provide screening assessment for risk and diagnosis of malnutrition, nutrition-related problems and obesity, as well as offer medical nutrition therapy, nutrition counseling, nutrition education and management, and coordination of enteral and parenteral nutrition. They also offer their expertise to community outreach programs through presentations and participation in health fairs for survivorship, health promotion and disease prevention.

FY 2022



Comparison



Financial Coordination

Lehigh Valley Topper Cancer Institute's Financial Coordination Services provides free assistance to patients as they go through their cancer journey. Our financial coordinators are happy to meet with patients and their families to help ease their concerns and work with them. They assist on questions about health insurance coverage, medication costs and medical bills. Financial Coordination Services provides the following services at no cost to our patients:

- Assist patients to get the most out of their insurance coverage and minimize potential out-of-pocket costs.
- Explain medical bills and out-of-pocket costs.
- Explore financial assistance options to cover medication costs.
- Help connect patients with financial aid opportunities through cancer support agencies.

FISCAL YEAR	ORAL MEDICATIONS ASSISTANCE	TOTAL NUMBER OF PATIENTS PROVIDED ASSISTANCE FOR ORAL MEDICATIONS	FAP* PATIENTS ASSISTED	PATHS PATIENTS REFERRED
2022	\$21,700,196	318	513	83
2021	\$17,559,634	311	626	122
2020	\$13,188,581	344	562	144
2019	\$7,805,256	299	616	130
2018	\$5,114,294	296	615	214
2017	\$5,419,690	176	577	220
2016	\$4,380,076	155	590	223
2015	\$3,058,370	109	655	221
2014	\$3,388,240	152	725	237
2013	\$4,366,205	202	749	294

* Fee Assistance Program

Oncology Social Work

Social workers are an integral part of the cancer care team by providing individual counseling and resource navigation, locating services that help with transportation and guiding patients through the process. Managing the costs associated with a cancer diagnosis can be overwhelming; our oncology social workers help patients find grant resources and financial assistance based on their diagnosis.

Counseling Services


Our licensed professional counselors support our patients and families by assisting with identifying goals and potential solutions to problems such as emotional turmoil caused by a cancer diagnosis. Our counselors help patients process their feelings and cope with the challenges that come with a cancer diagnosis. We have bilingual (Spanish/English) counselors available to assist our patients. Patients may see our counselors in person or virtually.

For fiscal year 2022, we had **329** referrals for counseling services.

FY 2022



Barriers addressed by social work referrals, FY 2022





Hackerman-Patz House

The Hackerman-Patz House at Lehigh Valley Hospital (LVH)–Cedar Crest is a convenient and affordable “home away from home” that offers an alternative to an expensive hotel or daily trips to and from your distant home.

Whether your loved one is a patient or you are receiving care, our goal remains the same: to offer you well-appointed, cozy accommodations and a supportive environment that allow you to focus on healing.

Our house is at 1260 S. Cedar Crest Blvd., Allentown, PA 18105. We are on the campus of LVH–Cedar Crest in Salisbury Township, directly off Interstate 78 (Route 309) at Exit 55 (Cedar Crest Boulevard). You’ll find us at the rear (south side) of the campus on a lovely, landscaped island across from the hospital’s emergency room.

We are a member of the Healthcare Hospitality Network, a nationwide network of more than 200 not-for-profit, family lodging facilities that offers warm, caring support to more than a quarter-of-a-million people each year.

HOUSE FEATURES

Everything in our house is designed to help make a stressful time in your life a little easier. And because you’ll be staying with other families facing similar circumstances, you’ll quickly discover you are not alone.

Please follow the signs for Hackerman-Patz House after you enter the hospital campus off Cedar Crest Boulevard. Our location puts us close to a variety of convenient dining and shopping options, as well as to services such as dry cleaners, banks and gas stations.

Front desk hours are 8 a.m.-4:30 p.m.

HOUSE AMENITIES INCLUDE:

- 20 smoke-free, well-appointed private rooms with your choice of one queen bed or two full beds, including eight handicapped-accessible rooms on the first floor
- All rooms include private, upscale bath, safe, TV and mini-fridge
- Kitchenette (Keurig coffee makers, microwaves, refrigerators and vending machine)
- Laundry facilities
- Great room for relaxing and meeting other guests
- Children’s playroom
- Library
- Outdoor patio
- Free Wi-Fi service
- Public computer and printer
- Free, on-site parking
- Use of hospital’s LVHN Fitness facility

Community Outreach

COLORECTAL CANCER PREVENTION EDUCATIONAL EVENT



March 24, 2022, on WebEx

45 in attendance, and event recording is posted to the LVHN event videos page

Physicians and other clinicians from Lehigh Valley Topper Cancer Institute, Colon-Rectal Surgery Associates and Eastern Pennsylvania Gastroenterology and Liver Specialists shared valuable

information on screening colonoscopies, risk factors, prevention and hereditary colorectal cancer. A Q&A panel with the physicians followed these presentations.

GYNECOLOGIC CANCER AWARENESS EVENT

Sept. 29, 2022, on Facebook Live

Christine Kim, MD, LVPG–Gynecologic Oncology, joined Steph Wells from B104 radio to answer frequently asked questions about gynecologic health, specifically ovarian and cervical cancers. A total of **1,400** people have viewed the program either by joining live or by watching the recorded video posted to our LVHN Facebook page.



PINK OUT AT THE PROMENADE

Oct. 20, 2022

In-person at The Promenade Shops at Saucon Valley with presentations also streamed on Facebook Live

150 in attendance, and has reached more than **1,000** people on Facebook Live

Physicians and other clinicians from Lehigh Valley Topper Cancer Institute and other LVHN entities shared important new information relating to breast health. Attendees had the opportunity to visit multiple resource tables including on nutrition, genetic counseling, cardio-oncology, Breast Health Services and clinical trials, as well as listen to our physicians speak on exciting updates in their specialties. More than \$1,000 was raised for the Pink Ribbon Fund, which assists breast cancer patients with nonmedical needs.

Survivorship Events

ADVANCES IN KIDNEY CANCER CARE SURVIVORSHIP EVENT

Oct. 18, 2022, on WebEx



40 in attendance, and event recording is posted to the LVHN event videos page

The event featured physicians and other clinicians from Lehigh Valley Topper Cancer Institute, including Suresh Nair, MD, Physician in Chief, and a survivorship panel that included our nurse navigator, dietitian and oncology social worker and a patient panelist. They provided valuable updates in kidney cancer care, noting advances in clinical trials and T-cell therapy. Tips for thriving in survivorship also were highlighted during this virtual celebration.




ADVANCES IN MELANOMA CANCER CARE SURVIVORSHIP EVENT

Oct. 25, 2022, on WebEx

85 in attendance, and event recording is posted to the LVHN event videos page

Physicians from Lehigh Valley Topper Cancer Institute and Advanced Dermatology Associates – along with a survivorship panel featuring our nurse navigator, dietitian and oncology social worker and patient panelists – provided valuable updates in melanoma cancer care. Program topics included detecting and preventing skin cancer, recent paradigm shifts in the surgical management of stage 3 melanoma and tips for thriving in survivorship.

Community Screenings




FREE SCREENING FOR ORAL CANCER

Is your throat sore? Do you have ear pain or difficulty chewing or swallowing? You may be at risk. Each year more than 50,000 people are diagnosed with oral cancer.

Don't risk it. Get screened.

April 25: Lehigh Valley Hospital-Hecktown Oaks

For your free appointment or for more information, call 888-402-LVHN (5846) or visit LVHN.org/oralscreenings.



Your health deserves a partner.

Oral cancer screenings were held on April 11 (LVH-Cedar Crest), April 18 (LVH-Muhlenberg) and April 25 (LVH-Hecktown Oaks).

A total of **51** people were screened for oral cancer by LVHN dentists and dental residents.

Skin cancer screenings were held on May 4 (LVH-Cedar Crest) and May 17 (LVH-Muhlenberg).

A total of **119** people were screened for skin cancer by dermatologists from Advanced Dermatology Associates and Zaladonis Dermatology Associates.



Free Screening for Skin Cancer With Lehigh Valley Topper Cancer Institute

A million new cases of skin cancer will be detected this year. If you have skin cancer, early diagnosis and treatment can save your life. Skin cancer most often occurs on sun-exposed skin, but it can occur anywhere on your body. According to the Skin Cancer Foundation, all skin cancers may be curable when found early.

Increase your odds
Lehigh Valley Topper Cancer Institute wants to help you spot and stop skin cancer early. Attend one of our free skin cancer screenings and increase your odds for survival - it only takes 15 minutes.

Why get screened?
Anyone can get skin cancer, but people with fair skin, freckles, light eyes or a history of blistering sunburns are at increased risk. Specialists from Advanced Dermatology Associates, Ltd and Zaladonis Dermatology Associates will screen for suspicious moles and freckles, discoloration or bleeding patches, and other marks that may indicate cancer.


Call 888-402-LVHN (5846) or visit LVHN.org/skinscreenings to schedule your free skin cancer screening today. Screenings are fast - they take only 15 minutes - and they could save your life.

Wednesday, May 4, 2022 6-8 p.m.
Lehigh Valley Hospital-Cedar Crest
John and Dorothy Morgan Cancer Center
Infusion Center/PHN,
Suite 5, Cedar Crest Blvd., Allentown

Tuesday, May 17, 2022 6-7:30 p.m.
Lehigh Valley Hospital-Muhlenberg
LVPC Hematology Oncology
Third Floor
2545 Schoenersville Road, Bethlehem


COVID-19 Mandates: We strongly encourage all attendees to be fully vaccinated against COVID-19. If you have been diagnosed with COVID-19 within two weeks of this visit, or are experiencing symptoms, please stay home. Masks are required.

LVHN.org | 888-402-LVHN (5846)



Patient and Family Advisory Council

The Patient and Family Advisory Council at Lehigh Valley Topper Cancer Institute maintains a high-quality patient and family centered care approach. The council consists of institute employees, as well as patients and their family members. Members of the council collaborate with the institute leadership in policy and program development, implementation and evaluation. They also assist in health care facility design. In 2022, our Patient Family Advisory Council played an integral role in developing a comprehensive Cancer Patient Guide. This guide was developed to provide helpful information and answer common questions that may cause stress or anxiety.



2022 PUBLICATIONS



PHYSICIAN SUBMISSIONS

ANGELO BACCALA, MD

Coleman JA, Yip W, Wong NC, Sjoberg DD, Bochner BH, Dalbagni G, Donat SM, Herr HW, Cha EK, Donahue TF, Pietzak EJ, Hakimi AA, Kim K, Al-Ahmadie HA, Vargas HA, Alvim RG, Ghafoor S, Benfante NE, Meraney AM, Shichman SJ, Kamradt JM, Nair SG, Baccala AA Jr, Palyca P, Lash BW, Rizvi MA, Swanson SK, Muina AF, Apolo AB, Iyer G, Rosenberg JE, Teo MY, Bajorin DF. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. *J Clin Oncol*. 2023 Mar 10;41(8):1618-1625. doi: 10.1200/JCO.22.00763. Epub 2023 Jan 5. PMID: 36603175.

RANJU GUPTA, MD

de Castria TB, Tang L, Queiroz MM, Awni BM, Paroder V, Shamseddine A, Bariani GM, Mukherji D, Matar CF, Fernandes GDS, El-Olayan A, Sabatin F, Elias R, Gupta R, Janjigian YY, Abou-Alfa GK. Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report. *J Gastrointest Oncol*. 2021 Dec;12(6):3123-3132. doi: 10.21037/jgo-21-287. PMID: 35070435; PMCID: PMC8748022.

Huff ML, Kalter JA, Chase RE, Gupta R. Trastuzumab Associated With Recurrent Severe Thrombocytopenia and Successful Use of Pertuzumab Monotherapy. *Cureus*. 2022 Jan 30;14(1):e21748. doi: 10.7759/cureus.21748. PMID: 35251819; PMCID: PMC8890586.

Gillespie EF, Mathis NJ, Vaynrub M, Santos Martin E, Kotecha R, Panoff J, Salner AL, McIntosh AF, Gupta R, Gulati A, Yerramilli D, Xu AJ, Bartelstein M, Guttmann DM, Yamada YJ, Lin D, Lapen K, Korenstein D, Pfister DG, Lipitz-Snyderman A, Yang JT. Multidisciplinary Treatment of Non-Spine Bone Metastases: Results of a Modified Delphi Consensus Process. *Clin Transl Radiat Oncol*. 2022 Apr 26;35:76-83. doi: 10.1016/j.ctro.2022.04.009. PMID: 35620018; PMCID: PMC91.

Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. *JCO Precis Oncol*. 2022 Oct 6:e2200306. doi: 10.1200/PO.22.00306. PMID: 36315917.

Gupta R, Sundlof DW, Tiu CT, Schadler KC, Cooper H, Rai S, Mann K, Barnaby J, Silverstein Fadlon CA, Corotto PS, Ahmad NV, Freudenberger R. Best processes for development of a successful cardio-oncology program in a community hospital. *Oncology Issues*, 37:6, 36-41. Epub 2022 November 14. DOI:10.1080/10463356.2022.2124806.

MORGAN HORTON, RN, BSN, CCRC

Wolfe Z, Friedland JC, Ginn S, Blackham A, Demberger L, Horton M, McIntosh A, Sheikh H, Box J, Knoerzer D, Federowicz B, Stuhlmiller TJ, Shapiro M, Nair S. Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma. *Melanoma Res*. 2022 Aug 1;32(4):295-298. doi: 10.1097/CMR.0000000000000830. Epub 2022 May 12. PMID: 35551160; PMCID: PMC9245552.

MAGED KHALIL, MD

Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. *J Clin Oncol*. 2022 Apr 20;40(12):1312-1322. doi: 10.1200/JCO.21.01485. Epub 2022 Jan 28. PMID: 35089812; PMCID: PMC9797229.

MELISSA KRATZ, RN, MSN, AOCNS

Leitao MM Jr, Zhou QC, Brandt B, Iasonos A, Sioulas V, Lavigne Mager K, Shahin M, Bruce S, Black DR, Kay CG, Gandhi M, Qayyum M, Scalici J, Jones NL, Paladugu R, Brown J, Naumann RW, Levine MD, Mendivil A, Lim PC, Kang E, Cantrell LA, Sullivan MW, Martino MA, Kratz MK, Kolev V, Tomita S, Leath CA 3rd, Boitano TKL, Doo DW, Feltmate C, Sugrue R, Olawaiye AB, Goldfeld E, Ferguson SE, Suhner J, Abu-Rustum NR. The MEMORY Study: Multicenter study of Minimally invasive surgery versus Open Radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. *Gynecol Oncol*. 2022 Sep;166(3):417-424. doi: 10.1016/j.jgyno.2022.07.002. Epub 2022 Jul 22. PMID: 35879128; PMCID: PMC9933771.

NICHOLAS LAMPARELLA, DO

Walsh EM, Guicalp A, Patil S, Edelweiss M, Ross DS, Razavi P, Modi S, Iyengar NM, Sanford R, Troso-Sandoval T, Gorsky M, Bromberg J, Drullinsky P, Lake D, Wong S, DeFusco PA, Lamparella N, Gupta R, Tabassum T, Boyle LA, Arumov A, Traina TA. Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study. *Breast Cancer Res Treat.* 2022 Oct;195(3):341-351. doi: 10.1007/s10549-022-06669-2. Epub 2022 Aug 20. PMID: 35986801.

BRADLEY LASH, MD

Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovskaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. *J Clin Oncol.* 2022 Apr 20;40(12):1312-1322. doi: 10.1200/JCO.21.01485. Epub 2022 Jan 28. PMID: 35089812; PMCID: PMC9797229.

Coleman JA, Yip W, Wong NC, Sjoberg DD, Bochner BH, Dalbagni G, Donat SM, Herr HW, Cha EK, Donahue TF, Pietzak EJ, Hakimi AA, Kim K, Al-Ahmadie HA, Vargas HA, Alvim RG, Ghafoor S, Benfante NE, Meraney AM, Shichman SJ, Kamradt JM, Nair SG, Baccala AA Jr, Palyca P, Lash BW, Rizvi MA, Swanson SK, Muina AF, Apolo AB, Iyer G, Rosenberg JE, Teo MY, Bajorin DF. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. *J Clin Oncol.* 2023 Mar 10;41(8):1618-1625. doi: 10.1200/JCO.22.00763. Epub 2023 Jan 5. PMID: 36603175.

ALYSON McINTOSH, MD

Gillespie EF, Mathis NJ, Vaynrub M, Santos Martin E, Kotecha R, Panoff J, Salner AL, McIntosh AF, Gupta R, Gulati A, Yerramilli D, Xu AJ, Bartelstein M, Guttman DM, Yamada YJ, Lin D, Lapen K, Korenstein D, Pfister DG, Lipitz-Snyderman A, Yang JT. Multidisciplinary Treatment of Non-Spine Bone Metastases: Results of a Modified Delphi Consensus Process. *Clin Transl Radiat Oncol.* 2022 Apr 26;35:76-83. doi: 10.1016/j.ctro.2022.04.009. PMID: 35620018; PMCID: PMC9127274.

Wolfe Z, Friedland JC, Ginn S, Blackham A, Demberger L, Horton M, McIntosh A, Sheikh H, Box J, Knoerzer D, Federowicz B, Stuhlmiller TJ, Shapiro M, Nair S. Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma. *Melanoma Res.* 2022 Aug 1;32(4):295-298. doi: 10.1097/CMR.0000000000000830. Epub 2022 May 12. PMID: 35551160; PMCID: PMC9245552.

TARA MORRISON, MD

Brastianos PK, Twohy EL, Gerstner ER, Kaufmann TJ, lafrate AJ, Lennerz J, Jeyapalan S, Piccioni DE, Monga V, Fadul CE, Schiff D, Taylor JW, Chowdhary SA, Bettegowda C, Ansstas G, De La Fuente M, Anderson MD, Shonka N, Damek D, Carrillo J, Kunschner-Ronan LJ, Chaudhary R, Jaeckle KA, Senecal FM, Kaley T, Morrison T, Thomas AA, Welch MR, Iwamoto F, Cachia D, Cohen AL, Vora S, Knopp M, Dunn IF, Kumthekar P, Sarkaria J, Geyer S, Carrero XW, Martinez-Lage M, Cahill DP, Brown PD, Giannini C, Santagata S, Barker FG 2nd, Galanis E. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. *J Clin Oncol.* 2023 Jan 20;41(3):618-628. doi: 10.1200/JCO.21.02371. Epub 2022 Oct 26. PMID: 36288512; PMCID: PMC9870228.

SURESH NAIR, MD

Postow MA, Goldman DA, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Smithy JW, Naito E, Cugliari MK, Raber V, Eton O, Nair SG, Panageas KS, Wolchok JD, Chapman PB. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). *J Clin Oncol.* 2022 Apr 1;40(10):1059-1067. doi: 10.1200/JCO.21.01570. Epub 2021 Dec 20. PMID: 34928709; PMCID: PMC8966970.

Wolfe Z, Friedland JC, Ginn S, Blackham A, Demberger L, Horton M, McIntosh A, Sheikh H, Box J, Knoerzer D, Federowicz B, Stuhlmiller TJ, Shapiro M, Nair S. Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma. *Melanoma Res.* 2022 Aug 1;32(4):295-298. doi: 10.1097/CMR.0000000000000830. Epub 2022 May 12. PMID: 35551160; PMCID: PMC9245552.

Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of

NRG Oncology RTOG 0129 and 0522. Head Neck. 2022 Jan;44(1):158-167. doi: 10.1002/hed.26915. Epub 2021 Nov 3. PMID: 34729846; PMCID: PMC8783635.

Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. J Immunother Cancer. 2022 Nov;10(11):e005780. doi: 10.1136/jitc-2022-005780. PMID: 36328377; PMCID: PMC9639138.

Sinicrope FA, Shi Q, Catteau A, Poage GM, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. JCO Precis Oncol. 2022 Aug;6:e2200010. doi: 10.1200/PO.22.00010. PMID: 35952316; PMCID: PMC9384943.

Wolfe Z, Blackham A, McIntosh A, Miller A, Sheikh H, Nair S. Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma. Cureus. 2022 Sep 25;14(9):e29573. doi: 10.7759/cureus.29573. PMID: 36312666; PMCID: PMC9596194.

PAUL PALYCA, MD

Coleman JA, Yip W, Wong NC, Sjoberg DD, Bochner BH, Dalbagni G, Donat SM, Herr HW, Cha EK, Donahue TF, Pietzak EJ, Hakimi AA, Kim K, Al-Ahmadie HA, Vargas HA, Alvim RG, Ghafoor S, Benfante NE, Meraney AM, Shichman SJ, Kamradt JM, Nair SG, Baccala AA Jr, Palyca P, Lash BW, Rizvi MA, Swanson SK, Muina AF, Apolo AB, Iyer G, Rosenberg JE, Teo MY, Bajorin DF. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol. 2023 Mar 10;41(8):1618-1625. doi: 10.1200/JCO.22.00763. Epub 2023 Jan 5. PMID: 36603175.

MUHAMMAD RIZVI, MD

Coleman JA, Yip W, Wong NC, Sjoberg DD, Bochner BH, Dalbagni G, Donat SM, Herr HW, Cha EK, Donahue TF, Pietzak EJ, Hakimi AA, Kim K, Al-Ahmadie HA, Vargas HA, Alvim RG, Ghafoor S, Benfante NE, Meraney AM, Shichman SJ, Kamradt JM, Nair SG, Baccala AA Jr, Palyca P, Lash BW, Rizvi MA, Swanson SK, Muina AF, Apolo AB, Iyer G, Rosenberg JE, Teo MY, Bajorin DF. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol. 2023 Mar 10;41(8):1618-1625. doi: 10.1200/JCO.22.00763. Epub 2023 Jan 5. PMID: 36603175.

ZACHARY WOLFE, MD

Wolfe Z, Friedland JC, Ginn S, Blackham A, Demberger L, Horton M, McIntosh A, Sheikh H, Box J, Knoerzer D, Federowicz B, Stuhlmiller TJ, Shapiro M, Nair S. Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma. Melanoma Res. 2022 Aug 1;32(4):295-298. doi: 10.1097/CMR.0000000000000830. Epub 2022 May 12. PMID: 35551160; PMCID: PMC9245552.

Wolfe Z, Blackham A, McIntosh A, Miller A, Sheikh H, Nair S. Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma. Cureus. 2022 Sep 25;14(9):e29573. doi: 10.7759/cureus.29573. PMID: 36312666; PMCID: PMC9596194.

POSTERS AND PRESENTATIONS

“Implementation of an Inpatient to Outpatient Communication Pathway to Improve Outcomes in High-Risk Oncology Patients”

by Kimberly Procaccino, RD, LDN, MBA, Janine Gilboy, RD, CSO, LDN, Jennifer Brennan, MS, RD, CSO, LDN, Erin Levine, RD, CSO, LDN, Amanda Stone, MS, RD, LDN, Alyse Wittman, RDN, LDN, presented virtually at the 2022 Academy of Nutrition and Dietetics Clinical Nutrition Management Symposium, March 2022.

“Special Populations” by Madison Greer featured Donna Colabroy, MSN, RN, AOCNS published on 06/07/2022, <https://voice.ons.org/>.

Lehigh Valley Topper Cancer Institute Locations

Lehigh Valley Topper Cancer Institute offers a range of services in convenient, patient-focused locations.

Lehigh Valley Physician Group (LVPG) practices provide services in Allentown, Bethlehem, East Stroudsburg, Easton, Hazleton, Lehigh, Pottsville and Scranton.

LEHIGH VALLEY TOPPER CANCER INSTITUTE

- John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital–Cedar Crest
- LVHN Cancer Center at Lehigh Valley Hospital–Muhlenberg
- LVHN Cancer Center–Carbon
- LVHN Cancer Center–Hazleton
- LVHN Cancer Center–Hecktown Oaks
- LVHN Cancer Center–Schuylkill
- Dale and Frances Hughes Cancer Center at Lehigh Valley Hospital–Pocono
- LVPG Radiation Oncology–Morgan Highway

BREAST HEALTH SERVICES

- Carbon Plaza Mall
- Lehigh Valley Health Network–Steamtown
- Health Center at Bangor
- Health Center at Bartonsville
- Health Center at Bath
- Health Center at Bethlehem Township
- Health Center at Moselem Springs
- Health Center at Trexlertown
- Health & Wellness Center at Hazleton
- Lehigh Valley Hospital–17th Street
- Lehigh Valley Hospital–Cedar Crest
- Health Center at Hecktown Oaks
- Lehigh Valley Hospital–Muhlenberg
- Lehigh Valley Hospital–Pocono
- Lehigh Valley Hospital–Schuylkill
- LVHN Imaging Center
- Mobile mammography coach



Lehigh Valley Health Network Cancer Program Affiliations

- American College of Surgeons' Commission on Cancer Accreditation (ACoS CoC)
- Member, Memorial Sloan Kettering Cancer Alliance
- Member, Michigan Cancer Research Consortium National Community Oncology Research Program (NCORP)
- Rapid Cancer Reporting System (RCRS)
- American College of Radiology (ACR) Radiation Oncology Practice Accreditation since 2012
- American College of Radiology (ACR) Breast Health Services Accreditation
- American College of Radiology (ACR) Breast Imaging Center of Excellence Designation (BICOE)
- American College of Radiology (ACR) Lung Cancer Screening Center
- National Accreditation Program for Breast Centers (NAPBC) Breast Health Service Accreditation
- National Quality Measures for Breast Centers (NQMBC) Certified Quality Breast Center of Excellence – Breast Health Services
- Quality Oncology Practice Initiative (QOPI) LVPG Hematology Oncology – certified since 2011
- U.S. News & World Report 2014-2015 High Performer – Cancer
- NCI Community Cancer Center Program Selected (NCCCP), April 2010-June 2014 (one of 21)
- National Committee Quality Assurance (NCQA) Patient-Centered Specialty Practice Level 2 Recognition – LVPG Hematology Oncology, March 20, 2014-March 2017

